Floatz logo

sh009

Non-Small Cell Lung Carcinoma

Nanjing Sanhome Pharmaceutical, Co., Ltd.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

1205 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Veliparib
AbbVie
Phase 3BBB

View all 50 →

Same molecule, other indications

sh009 is also rated in:

liver cancerDormant
CC
Indicative ·
43 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
breast cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →